Kazumi Iwata

Dr. Kazumi Iwata

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Neuron
Verified
Journal Article
Closed access
KNKengo Nomura
Kengo Nomura
MNMiho Nakanishi
Miho Nakanishi
FIFumiyoshi Ishidate
Fumiyoshi Ishidate
KIKazumi Iwata
Kazumi Iwata
ATAkiyuki Taruno
Akiyuki Taruno

11 February 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
RWRuolei Wang
Ruolei Wang
LLLirong Liang
Lirong Liang
MMMisaki Matsumoto
Misaki Matsumoto
KIKazumi Iwata
Kazumi Iwata
Atsushi UmemuraAtsushi Umemura
Atsushi Umemura
Feng HeFeng He
Feng He
The imbalance between reactive oxygen species (ROS) production and clearance causes oxidative stress and ROS, which play a central role in regulating cell and tissue physiology and pathology. Contingent upon concentration, ROS influence cancer development in contradictory ways, either stimulating cancer survival and growth or causing cell death. Cells developed evolutionarily conserved programs to sense and adapt redox the fluctuations to regulate ROS as either signaling molecules or toxic insults. The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2)-KEAP1 system is the master regulator of cellular redox and metabolic homeostasis. NRF2 has Janus-like roles in carcinogenesis and cancer development. Short-term NRF2 activation suppresses tissue injury, inflammation, and cancer initiation. However, cancer cells often exhibit constitutive NRF2 activation due to genetic mutations or oncogenic signaling, conferring advantages for cancer cells’ survival and growth. Emerging evidence suggests that NRF2 hyperactivation, as an adaptive cancer phenotype under stressful tumor environments, regulates all hallmarks of cancer. In this review, we summarized the source of ROS, regulation of ROS signaling, and cellular sensors for ROS and oxygen (O2), we reviewed recent progress on the regulation of ROS generation and NRF2 signaling with a focus on the new functions of NRF2 in cancer development that reach beyond what we originally envisioned, including regulation of cancer metabolism, autophagy, macropinocytosis, unfolded protein response, proteostasis, and circadian rhythm, which, together with anti-oxidant and drug detoxification enzymes, contributes to cancer development, metastasis, and anticancer therapy resistance.

1 May 2018 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
KIKazumi Iwata
Kazumi Iwata
KMKuniharu Matsuno
Kuniharu Matsuno
AMAyumi Murata
Ayumi Murata
KZKai Zhu
Kai Zhu
HFHitomi Fukui
Hitomi Fukui
CYChihiro Yabe-Nishimura
Chihiro Yabe-Nishimura

5 September 2007 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
MKMasato Katsuyama
Masato Katsuyama
MCMUHAMMER OZGUR CEVIK
MUHAMMER OZGUR CEVIK
NANoriaki Arakawa
Noriaki Arakawa
TKTomoko Kakehi
Tomoko Kakehi
TNToru Nishinaka
Toru Nishinaka
CYChihiro Yabe‐Nishimura
Chihiro Yabe‐Nishimura
NADPH oxidase is a major source of the superoxide produced in cardiovascular tissues. Expression of NOX1, a catalytic subunit of NADPH oxidase, is induced by various vasoactive factors, including angiotensin II, prostaglandin (PG) F2α and platelet‐derived growth factor (PDGF). To clarify the molecular basis of this transcriptional activation, we delineated the promoter region of the NOX1 gene. RT‐PCR and 5′‐rapid amplification of cDNA ends‐based analyses revealed a novel 5′‐terminal exon of the rat NOX1 gene located approximately 28 kb upstream of the exon containing the start codon. Both PGF2α and PDGF enhanced the transcriptional activity of the − 3.6 kb 5′‐flanking region of the NOX1 gene in A7r5 cells, a rat vascular smooth muscle cell line. A PGF2α‐response element was located between −146 and −125 in the 5′‐flanking region containing a consensus binding site for myocyte enhancer factor 2 (MEF2), to which binding of MEF2 was augmented by PGF2α. Gene silencing of MEF2B by RNA interference significantly suppressed the expression of NOX1, while silencing of activating transcription factor (ATF)‐1, previously implicated in up‐regulation of NOX1, abolished the PGF2α‐ or PDGF‐induced expression of MEF2B. These results indicate that superoxide production in vascular smooth muscle cells is regulated by the ATF‐1–MEF2B cascade by induction of the expression of the NOX1 gene.

17 January 2019 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
XWXiaopeng Wen
Xiaopeng Wen
KIKazumi Iwata
Kazumi Iwata
KIKeiko Ikuta
Keiko Ikuta
XZXueqing Zhang
Xueqing Zhang
KZKai Zhu
Kai Zhu
CYChihiro Yabe‐Nishimura
Chihiro Yabe‐Nishimura
The involvement of superoxide‐generating NADPH oxidase (NOX) in the cytotoxic effects of cigarette smoke extracts has been documented. However, the underlying molecular mechanisms and NOX isoform involved have not been fully clarified. Among the different NADPH oxidase isoforms identified so far, NOX1 and NOX4 were found to be expressed in rat H9c2 cardiomyocytes. When H9c2 cells were exposed to acrolein or methyl vinyl ketone (MVK), major toxic components of cigarette smoke extracts, a dose‐dependent decline in cell viability was observed. Unexpectedly, disruption of Nox1 as well as Nox4 significantly exacerbated cytotoxicity induced by acrolein or MVK. Compared with Nox4‐disrupted cells, Nox1‐disrupted cells were more vulnerable to acrolein and MVK at lower concentrations. Disruption of Nox1 markedly attenuated the levels of total and reduced glutathione (GSH) in H9c2 clones. Reduction in the cystine level in the culture medium to deplete intracellular GSH significantly exacerbated acrolein or MVK‐induced cytotoxicity. Nox1 disruption neither attenuated the level of glutamate–cystine antiporter protein nor the activity of glutamate–cysteine ligase, both rate‐limiting factors for GSH synthesis. On the other hand, increased expression of multidrug resistance‐associated protein 1 (MRP1), which mediates glutathione efflux, was demonstrated in Nox1‐disrupted cells. The augmented toxicity of acrolein and MVK in these cells was partially but significantly blunted in the presence of an MRP1 inhibitor, reversan. Taken together, these results show that NOX1/NADPH oxidase regulates the expression of MRP1 to maintain intracellular GSH levels in cardiomyocytes and protect against cytotoxic components of cigarette smoke extracts. A novel crosstalk between NOX1 and MRP1 was demonstrated in this study.

1 January 1996 in The Japanese Journal of Pharmacology
Verified
Journal Article
Open access
NMNaofumi Murakami
Naofumi Murakami
HTHiroshi Takase
Hiroshi Takase
TTTakako Tomita
Takako Tomita
KIKazumi Iwata
Kazumi Iwata
TNTomohiro Naruse
Tomohiro Naruse
Both analgesic and ulcerogenic activities of d-2-[4-(3-methyl-2-thienyl)phenyl] propionic acid (M-5011), a novel non-steroidal anti-inflammatory drug (NSAID), were compared with those of indomethacin (IND), ketoprofen (KP), diclofenac sodium (DIF), zaltoprofen (ZLT) and tiaprofenic acid (TIA) in mice. All orally administered NSAIDs including M-5011 inhibited kaolin-induced writhing in a dose-dependent manner. M-5011 had an effective antinociceptive activity (ED50 value) of 0.63 mg/kg, being more potent than ZLT (16.80 mg/kg) and TIA (4.78 mg/kg), equipotent to DIF (0.68 mg/kg), and less potent than IND (0.21 mg/kg) and KP (0.28 mg/kg). All drugs tested significantly reduced peritoneal 6-ketoprostaglandin F1 alpha (6-keto-PGF1 alpha) levels at the peak kaolin-induced writhing time (7.5 min post-kaolin injection) without affecting peritoneal bradykinin (BK) levels. Antinociceptive effects of all drugs were closely correlated with inhibition of peritoneal 6-keto-PGF1 alpha levels. Ulcerogenic activities (UD50 value) of M-5011 in the stomach and small intestines were 88.23 and 46.09 mg/kg, respectively. UD50 values of other drugs in the stomach and small intestines were as follows: 8.96 and 4.78 mg/kg, 20.04 and 10.75 mg/kg, 4.19 and 2.24 mg/kg, 62.86 and 46.55 mg/kg, and 110.92 and 54.78 mg/kg for IND, KP, DIF, TIA, and ZLT, respectively. Thus, the safety indexes (UD50/ED50) of the stomach (or small intestine) for M-5011, IND, KP, DIF, TIA and ZLT were 140.05 (73.16), 42.67 (22.76), 71.57 (38.39), 6.16 (3.29), 13.15 (9.74) and 6.60 (3.26), respectively. These findings suggest that M-5011 is a useful NSAID that shows potent antinociceptive effects with low ulcerogenic activities.